Hospital da Luz at the National Congress of Nuclear Medicine
The 16th National Congress of Nuclear Medicine, promoted by the Portuguese society of the specialty, took place in Lisbon, between 23 and 25 November, at Museu do Oriente, and counted with a large involvement from Hospital da Luz Lisboa collaborators, who organized round tables, presented communications and posters.
Maria do Rosário Vieira, coordinator of the Department of Molecular Medicine from Hospital da Luz Lisboa, was the responsible for the organization of a round table dedicated to neuroendocrine tumours. In this discussion, participated also Teresa Timóteo, Hospital da Luz oncologist.
Among the talks hold, we highlight the conference by Rui Maio, clinical director of Hospital Beatriz Ângelo and assistant-director of Hospital da Luz Lisboa, entitled “The extent of the disease as prognostic value for PRRT with 177Lu-DOTA-TATE”, and by Vanessa Sousa, intern of Nuclear Medicine at Hospital da Luz Lisboa, about “Prognostic definition after therapeutics with PRRT: influence of imaging with two different radiopharmaceuticals, 68Ga-DOTA-NOC and 18F-FDG”.
In an oral communication, Vanessa Sousa made a revision of 68Ga-PSMA-11 tests (innovating and prostate specific radiopharmaceutical used in the evaluation of prostatic tumours), conducted at Hospital da Luz. It is worth mentioning that in the Lisbon area, there are only two centres doing this study.
Finally, two posters from Hospital da Luz team were presented: “PET-CT 68Ga-PSMA – Dynamic Study. Technical aspects and preliminary evaluation”, presented by technician Denise Calado, and “Evaluation of dose rate after therapeutics with iode 131 for thyroid differentiated carcinoma”, presented by technician Ricardo Jorge.